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Introduction
Topiramate is the only approved oral preventive drug
for chronic migraine (CM). However, we usually use
other preventive drugs of prevention of frequent episo-
dic migraine. Zonisamide is a neuromodulator that has
showed efficacy in prevention of CM.
Objectives
To evaluate the efficacy of zonisamide after three
months of therapy in CM patients (IHS-2006 criteria)
that present inefficacy/intolerance/contraindication to
topiramate, sodium valproate, â-blocks and flunarizine.
Methods
Doses ZNS: 50-200mg. Primary end-point: Number of
migraine days-NMD: Ineffective response-Inef(reduction
of days<50%), good-G(50-75%), excellent-Exc(>75%).
Secondary end-points: number of migraine episodes-
NME; number of headache days-NHD; drug overuse;
consumption of triptans and NSAIDs; EVA and MIDAS
score, effective mean dose of ZNS, adverse events.
Results
We prospectively included 27 patients (May 2011-May
2012), 85.2% women. Twelve patients (44.4%) presented
16 adverse events (100% mild). Four of them-14.8% left
the therapy. NMD, in the 23 patients who finished the
three months follow-up, was Exc-39.1%, G-43.5%, and
Inef-17.4%; NME was Exc-30.4%, G-43.5%, and Inef-
26.1%; and NHD was Exc-34.8%, G-39.1%, and Inef-26.1%.
Drug overuse disappeared in 47.8% of overusers. The con-
sumption of triptans and NSAIDs decreased 54.3%, and
65.7%. The EVA score decreased 3.7 points (56.2%), and
MIDAS scale score decreased 14.6 points (48.7%). Effective
mean doses of ZNS: 106.6mg/night.
Conclusion
Zonisamide presents a good profile of efficacy (70.3% of
responses) and an acceptable tolerance. It could be a use-
ful therapeutic option in CM patients intolerants, refrac-
tory, or with contraindications for topiramate, and the
other drugs preventive drugs of migraine.
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